Literature DB >> 22322826

Characterization of a novel mouse monoclonal antibody, clone 1E8.33, highly specific for human procollagen 11A1, a tumor-associated stromal component.

Marcos García-Ocaña1, Fernando Vázquez, Carmen García-Pravia, Nelson Fuentes-Martínez, Primitiva Menéndez-Rodríguez, Florentino Fresno-Forcelledo, Luis Barneo-Serra, Jokin Del Amo-Iribarren, Laureano Simón-Buela, Juan R De Los Toyos.   

Abstract

A novel IgG1, κ mouse monoclonal antibody (clone 1E8.33) to human procollagen 11A1 has been generated. This antibody is poorly mutated, essentially in germ line configuration; its complementarity determining regions (CDRs) are especially rich in tyrosine and serine residues. The epitope recognized is encompassed in the YNYGTMESYQTEAPR amino acid stretch within the variable region of human procollagen 11A1. Human procollagens 5A1 and 11A1 are very similar. However, this antibody does not cross-react with human procollagen 5A1. In human breast tumors, only the activated peritumoral myofibroblasts show a strong intracytoplasmic staining with this antibody. As procollagen 11A1 is overexpressed in the stroma of human tumors with desmoplastic reaction, this antibody represents a valuable tool for diagnostic purposes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22322826     DOI: 10.3892/ijo.2012.1360

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  Gene expression study in positron emission tomography-positive abdominal aortic aneurysms identifies CCL18 as a potential biomarker for rupture risk.

Authors:  Audrey Courtois; Betty V Nusgens; Roland Hustinx; Gauthier Namur; Pierre Gomez; Helena Kuivaniemi; Jean-Olivier Defraigne; Alain C Colige; Natzi Sakalihasan
Journal:  Mol Med       Date:  2015-03-24       Impact factor: 6.354

Review 2.  COL11A1/(pro)collagen 11A1 expression is a remarkable biomarker of human invasive carcinoma-associated stromal cells and carcinoma progression.

Authors:  Fernando Vázquez-Villa; Marcos García-Ocaña; José A Galván; Jorge García-Martínez; Carmen García-Pravia; Primitiva Menéndez-Rodríguez; Carmen González-del Rey; Luis Barneo-Serra; Juan R de Los Toyos
Journal:  Tumour Biol       Date:  2015-03-12

3.  Validation of COL11A1/procollagen 11A1 expression in TGF-β1-activated immortalised human mesenchymal cells and in stromal cells of human colon adenocarcinoma.

Authors:  José A Galván; Jorge García-Martínez; Fernando Vázquez-Villa; Marcos García-Ocaña; Carmen García-Pravia; Primitiva Menéndez-Rodríguez; Carmen González-del Rey; Luis Barneo-Serra; Juan R de los Toyos
Journal:  BMC Cancer       Date:  2014-11-23       Impact factor: 4.430

4.  Collagen Type XI Alpha 1 Expression in Intraductal Papillomas Predicts Malignant Recurrence.

Authors:  Javier Freire; Lucia García-Berbel; Pilar García-Berbel; Saray Pereda; Ainara Azueta; Pilar García-Arranz; Ana De Juan; Alfonso Vega; Ángela Hens; Ana Enguita; Pedro Muñoz-Cacho; Javier Gómez-Román
Journal:  Biomed Res Int       Date:  2015-09-13       Impact factor: 3.411

5.  Overexpression of COL11A1 by cancer-associated fibroblasts: clinical relevance of a stromal marker in pancreatic cancer.

Authors:  Carmen García-Pravia; José A Galván; Natalia Gutiérrez-Corral; Lorena Solar-García; Eva García-Pérez; Marcos García-Ocaña; Jokin Del Amo-Iribarren; Primitiva Menéndez-Rodríguez; Juan García-García; Juan R de Los Toyos; Laureano Simón-Buela; Luis Barneo
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

6.  A new aggressive xenograft model of human colon cancer using cancer-associated fibroblasts.

Authors:  Ester Fernando-Macías; Maria Teresa Fernández-García; Eva García-Pérez; Belén Porrero Guerrero; Camilo López-Arévalo; Raquel Rodríguez-Uría; Sandra Sanz-Navarro; José Fernando Vázquez-Villa; María Carmen Muñíz-Salgueiro; Laura Suárez-Fernández; José A Galván; Clara Barneo-Caragol; Marcos García-Ocaña; Juan R de Los Toyos; Luis Barneo-Serra
Journal:  PeerJ       Date:  2020-06-03       Impact factor: 2.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.